Biochemical Markers as Surrogate End Points of Joint Disease
- 19 March 2008
- book chapter
- Published by Springer Nature
Abstract
No abstract availableThis publication has 92 references indexed in Scilit:
- Pathogenesis and management of pain in osteoarthritisThe Lancet, 2005
- Cartilage glycosaminoglycan loss in the acute phase after an anterior cruciate ligament injury: Delayed gadolinium‐enhanced magnetic resonance imaging of cartilage and synovial fluid analysisArthritis & Rheumatism, 2005
- Can we identify a ‘high risk’ patient profile to determine who will experience rapid progression of osteoarthritis?Osteoarthritis and Cartilage, 2004
- Biomarkers in systemic lupus erythematosus: I. General overview of biomarkers and their applicabilityArthritis & Rheumatism, 2004
- The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritisHealth and Quality of Life Outcomes, 2003
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Knee adduction moment, serum hyaluronan level, and disease severity in medial tibiofemoral osteoarthritisArthritis & Rheumatism, 1998
- Perspective: Validating Surrogate Markers--Are We Being Naive?The Journal of Infectious Diseases, 1997
- Cartilage matrix molecules in serum and synovial fluidCurrent Opinion in Rheumatology, 1995
- Cartilage Content of an Immature DogConnective Tissue Research, 1989